- Home
- XENE
as 02-21-2025 4:00pm EST
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Upcoming Earnings Alert:
Get ready for potential market movements as Xenon Pharmaceuticals Inc. XENE prepares to release earnings report on 27 Feb 2025.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 3.3B | IPO Year: | 2014 |
| Target Price: | $57.00 | AVG Volume (30 days): | 445.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.53 - $50.99 | Next Earning Date: | 02-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1599.99% |
Stock Insider Trading Activity of Xenon Pharmaceuticals Inc. (XENE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MORTIMER IAN | XENE | PRESIDENT & CEO | Jan 23 '25 | Sell | $40.45 | 55,000 | $2,213,996.75 | 31,302 | |
| AULIN SHERRY | XENE | Chief Financial Officer | Dec 18 '24 | Sell | $41.21 | 18,709 | $770,911.67 | 0 |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
MT Newswires
11 days ago
Deutsche Bank Initiates Coverage on Xenon Pharmaceuticals With Buy Rating, $67 Price Target
Simply Wall St.
20 days ago
We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate
MT Newswires
25 days ago
Xenon Pharmaceuticals Insider Sold Shares Worth $2,213,997, According to a Recent SEC Filing
MT Newswires
a month ago
Wedbush Cuts Price Target on Xenon Pharmaceuticals to $43 From $46, Keeps Outperform Rating
GlobeNewswire
a month ago
Xenon Outlines Key Corporate Milestone Opportunities for 2025
GlobeNewswire
a month ago
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Zacks
2 months ago
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Compare XENE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.